Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials

Area of Science:

• Psychiatry
• Clinical Psychology
• Psychotherapy Research

Background:

• The therapeutic alliance is a critical factor in treatment outcomes for major depressive disorder.
• Understanding factors influencing alliance development is essential for optimizing patient care.
• Patient preferences for specific treatment modalities are often elicited but their impact on alliance is not fully understood.

Purpose of the Study:

• To investigate how patient preferences for psychotherapy versus pharmacotherapy influence the development of the therapeutic alliance.
• To examine the relationship between treatment preference congruence and alliance formation in a randomized controlled trial (RCT).

Main Methods:

• Seventy-five patients with major depressive disorder were enrolled in an RCT comparing supportive-expressive psychotherapy with sertraline or placebo.
• Therapeutic alliance was assessed at multiple time points: pre-treatment, and weeks 3, 5, and 9.
• Patient preference for psychotherapy or pharmacotherapy was recorded prior to treatment initiation.

Main Results:

• Patients preferring psychotherapy who received it showed increased alliance over time.
• Patients preferring psychotherapy who received medication (sertraline or placebo) showed decreased alliance.
• Patients preferring pharmacotherapy showed no significant differences in alliance development regardless of treatment received.
• These findings persisted even after controlling for symptom severity.

Conclusions:

• Congruence between a patient's preferred treatment and their assigned treatment significantly influences therapeutic alliance development.
• Considering patient preferences in RCTs and clinical practice may enhance the therapeutic alliance, a key predictor of treatment success.
• Treatment preference should be a key consideration in the design and execution of clinical trials and patient management strategies.